ID: h-1fd37610f6
Hypothesis
Anti-inflammatory microglial reprogramming via cystatin-C/TREM2 axis
Systemic tumors secrete cystatin C which crosses the BBB via LRP1 and engages TREM2 on microglia, shifting neuroinflammatory profile from pro-inflammatory (IL-1β, TNF-α, IL-6) to anti-inflammatory/regulatory (IL-10, TGF-β).
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 3 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
Systemic tumors secrete cystatin C which crosses the BBB via LRP1 and engages TREM2 on microglia, shifting neuroinflammatory profile from pro-inflammatory (IL-1β, TNF-α, IL-6) to anti-inflammatory/regulatory (IL-10, TGF-β). This represents the most druggable pharmacology story, though the field's first major TREM2 agonist phase 2 (AL002) missed its clinical primary endpoint despite biomarker engagement. Clinical translation requires biomarker-enriched populations and likely combination therapy with anti-amyloid antibodies.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Amyloid-beta Plaques<br/>Phospholipid Ligands"]
B["TREM2 Receptor<br/>Ligand Binding"]
C["TYROBP/DAP12<br/>ITAM Phosphorylation"]
D["SYK Kinase<br/>Activation"]
E["PLCG2<br/>IP3 + DAG Generation"]
F["Ca2+ Release<br/>Cytoskeletal Remodeling"]
G["Microglial Phagocytosis<br/>Plaque Compaction"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#81c784,color:#81c784⚖️ Evidence
⚖️ Evidence Matrix3 supports2 contradicts
Supports
TREM2 stimulation suppresses LPS-induced inflammatory cytokines in primary microglia
Supports
Cancer patients show elevated systemic cystatin C and reduced CSF inflammatory markers
Contradicts
AL002 phase 2 TREM2 agonist showed CNS target engagement but missed clinical primary endpoint in early AD
Contradicts
Broad anti-inflammatory effects could paradoxically impair beneficial debris clearance
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — TREM2
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for TREM2/TYROBP from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for TREM2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 0.9%
Volatility
Low
0.0031
Events (7d)
3
Price History
▼11.8%💾 Resource Usage
LLM Tokens
11,154
$0.0335
Total Cost
$0.0335
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF 5xFAD mice receive bilateral intracerebroventricular infusion of recombinant human cystatin-C (10 μg/day) for 14 days starting at 6 months of age, THEN cortical microglia will show ≥50% increase in | Measurable shift from M1-like to M2-like microglial phenotype quantified by flow cytometry and spatial transcriptomics of cortical tissue; neurobehavioral impro | — no observation — | pending | 0.68 |
| IF cancer patients with solid tumors are stratified by baseline serum cystatin-C into high (top tertile, >2.8 mg/L) vs low (bottom tertile, <1.4 mg/L) groups, THEN patients in the high cystatin-C coho | Inverse correlation between systemic cystatin-C concentration and CNS pro-inflammatory/anti-inflammatory cytokine ratio; detectable cystatin-C in paired CSF sam | — no observation — | pending | 0.62 |
🔮 Falsifiable Predictions (2)
pendingconf 68%
IF 5xFAD mice receive bilateral intracerebroventricular infusion of recombinant human cystatin-C (10 μg/day) for 14 days starting at 6 months of age, THEN cortical microglia will show ≥50% increase in Arg1+ and CD206+ immunoreactivity with ≥40% reduction in Iba1+/CD16b+ pro-inflammatory microglia wi
Predicted outcome: Measurable shift from M1-like to M2-like microglial phenotype quantified by flow cytometry and spatial transcriptomics of cortical tissue; neurobehavi
Falsification: Pro-inflammatory microglial markers (CD16/32, iNOS) show no significant change or increase; anti-inflammatory markers (Arg1, CD206) do not increase; amyloid plaque burden remains unchanged.
pendingconf 62%
IF cancer patients with solid tumors are stratified by baseline serum cystatin-C into high (top tertile, >2.8 mg/L) vs low (bottom tertile, <1.4 mg/L) groups, THEN patients in the high cystatin-C cohort will exhibit ≥30% lower CSF IL-1β/IL-10 ratio and ≥25% higher TGF-β1 levels compared to low cysta
Predicted outcome: Inverse correlation between systemic cystatin-C concentration and CNS pro-inflammatory/anti-inflammatory cytokine ratio; detectable cystatin-C in pair
Falsification: No significant difference in CSF cytokine profiles between high vs low cystatin-C groups; cystatin-C not detectable in CSF; CSF cytokines unchanged regardless of serum levels.
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.